Details for Patent: 8,921,348
✉ Email this page to a colleague
Which drugs does patent 8,921,348 protect, and when does it expire?
Patent 8,921,348 protects KORLYM and is included in one NDA.
Summary for Patent: 8,921,348
Title: | Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists |
Abstract: | The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL. |
Inventor(s): | Belanoff; Joseph K. (Woodside, CA) |
Assignee: | Corcept Therapeutics, Inc. (Menlo Park, CA) |
Application Number: | 14/065,792 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,921,348 |
Patent Claim Types: see list of patent claims | Use; Delivery; Device; |
Drugs Protected by US Patent 8,921,348
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Corcept Therap | KORLYM | mifepristone | TABLET;ORAL | 202107-001 | Feb 17, 2012 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATING CUSHING'S SYNDROME | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |